CRISPR Therapeutics AG (CRSP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
CRISPR Therapeutics AG (CRSP) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (55/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+61.2% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How CRSP Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | 44% | -18933.6% | -$581.6M | -$345.9M | -30.4% |
| FY 2024 | $37.3M | 44% | -1250.4% | -$366.3M | -$144.7M | -20.8% |
| FY 2023 | $371.2M | 44% | -60% | -$153.6M | -$277.1M | -10.1% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CRSP)
- ✓Live walkthrough of CRSP's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
CRSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRSP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRSP. Explore sector supply chains on /butterfly.
CRSP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is CRISPR Therapeutics AG (CRSP)?
In FY 2025 (10-K), CRSP converted $3.5M of revenue into a 44% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).